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Abstract 
The advent of biodegradable polymer-encapsulated drug nanoparticles has made the 
pulmonary route of administration an exciting area of drug delivery research. Chitosan, a 
natural biodegradable and biocompatible polysaccharide has received enormous attention as a 
carrier for drug delivery. Recently, nanoparticles of chitosan (CS) and its synthetic 
derivatives have been investigated for the encapsulation and delivery of many drugs with 
improved targeting and controlled release. Herein, recent advances in the preparation and use 
of micro-/nanoparticles of chitosan and its derivatives for pulmonary delivery of various 
therapeutic agents (drugs, genes, vaccines) are reviewed. Although chitosan has wide 
applications in terms of formulations and routes of drug delivery, this review is focused on 
pulmonary delivery of drug-encapsulated nanoparticles of chitosan and its derivatives. In 
addition, the controversial toxicological effects of chitosan nanoparticles for lung delivery 
will also be discussed. 
 
Key words: chitosan, chitosan derivatives, nanoparticles, inhalation, biodegradable, 
pulmonary drug delivery  
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1. Introduction 
Drug delivery directly into the lungs is an efficient method to achieve both local and systemic 
effects for therapeutic agents. The advantages of pulmonary drug delivery include superior 
efficacy, low toxicity, and sustained and rapid onset of action, which other drug 
administration routes (except injections) cannot achieve. The large epithelial surface area, the 
high organ vascularization, extremely thin absorptive alveolar epithelial membrane, the 
immense capacity for solute exchange, and good blood supply are notable factors that make 
the lung an ideal drug delivery route for the treatment of both local and systemic disorders. 
Delivery of drugs into the lungs ensures low systemic side-effects compared with oral or 
intravenous administration and no first-pass metabolism, which is a common problem for 
orally administered drugs. Direct delivery of drugs into the lungs also enables lower doses 
with an equivalent therapeutic action compared to oral or parenteral routes.
1
  For efficient 
pulmonary delivery, aerosol particles containing drug should be small enough (<
avoid contact with the upper respiratory tract and reach the alveolar space within the deep 
lung. Although not fully established, further reduction in size to the nm range results in 
increased deep lung deposition, with nanoparticles of the size <100 nm found to be 
particularly efficient.
2
  
 
Many biodegradable polymeric micro/nanocarriers have been extensively investigated for 
lung delivery of various drugs.
3, 4
 For example, poly(lactic-co-glycolic) acid (PLGA),
5-8
 
poly(ethyleneglycol) (PEG)
9
,  polyethylenimine (PEI)
10
 and chitosan (CS) 
8, 11-13
 have been 
studied for pulmonary drug delivery. The hydrophobic character of PLGA limits the 
encapsulation efficiency and subsequent delivery of hydrophilic drugs in PLGA based 
nanoparticles.
14
 The hydrophobicity can be reduced by attaching hydrophilic PEG groups 
onto the PLGA backbone and such approaches have opened a window for developing various 
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types of PEG-PLGA copolymers for encapsulating both hydrophilic and hydrophobic drugs. 
Depending on the molecular weight, PEG alone can encapsulate mostly hydrophilic drugs 
and is capable of releasing the encapsulated drug into the target area. 
15
 On the other hand, 
CS can accommodate both hydrophilic and hydrophobic drugs due to its amphiphilic 
properties. 
16
 Among the natural polymers investigated for lung delivery of various drugs,
4
 
CS is recognised as a non-toxic, biocompatible (especially with respiratory cells)
17, 18
 and 
biodegradable 
17, 19, 20
 polymer.  The advantages of CS over other biodegradable polymers are 
that it is mucoadhesive 
21-24
 and an absorption enhancer.
24
  CS has the ability to modify the 
morphology of particles and thus increase the dispersibility of particles leading to increased 
deposition into the lungs.
17
 CS and its derivative N-trimethyl chitosan (compound 2, Figure 
1) are well known as permeation enhancers
25, 26
 of various drugs. In addition, CS has inherent 
immunogenicity which is absent in other polymers, and this enables its use as an adjuvant for 
vaccine delivery into the lungs.
27, 28
 Therefore, in this review, we have focused on the use of 
CS and its derivatives in investigating pulmonary delivery of various therapeutic agents, 
including small molecule drugs, proteins/peptides, vaccines and genes. The ongoing 
toxicological debate associated with CS nanoparticles (NPs) for lung delivery is discussed.  
  
2. Chitosan, a promising polymer 
Chitosan (CS, 1) is a linear polysaccharide composed primarily of β-(14)-linked 
glucosamine (2-amino-2-deoxy-β-D-glucopyranose). It is obtained by deacetylation of 
naturally occurring chitin under basic conditions and thus contains varying amounts of N-
acetylglucosamine (2-acetamido-2-deoxy-β-D-glucopyranose) due to incomplete 
deacetylation (Fig. 1).   
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CS is insoluble in aqueous solutions at neutral pH; however, it is soluble in aqueous acidic 
media (pH<5) as the basic amino groups (-NH2) are protonated (-NH3
+
) and therefore, it is 
positively charged. The cationic charge of CS provides mucoadhesive properties
13, 22, 23
 that 
enable it to adhere to the mucosa of lung epithelial cells and contribute to the prolonged 
release of encapsulated drugs.
29-31
 The positively charged CS has been found to improve drug 
absorption by opening the intercellular tight junctions of the lung epithelium.
24, 32
 The 
mucoadhesive properties of spray dried CS microspheres containing montelukast sodium was 
found to increase with increasing concentrations of CS in the formulation.
33
  It has also been 
reported to promote drug transepithelial transport in the alveolar area.
34
 Furthermore, CS 
itself has been reported to have bactericidal properties.
35, 36
The antibacterial effects of CS 
have been attributed to an electrostatic interaction between the protonated amino groups of 
CS and the phosphoryl groups and lipopolysaccharides of bacterial cell membranes, which 
destroys the membrane and releases the cellular contents. These properties additionally aid 
the lung delivery of antibiotics containing CS against infectious diseases. Depending on the 
molecular weight, degree of deacetylation (DD) and hydrolysis time, CS undergoes 
enzymatic depolymerisation in the presence of lysozyme,
37
 which is the most important  
antimicrobial enzyme present in secretions of the respiratory tract and that’s why it has been 
studied extensively for delivering various antibacterial agents into the lungs, as discussed in 
section 4.1.   
 
A comparative study on the oral versus pulmonary delivery of calcitonin in the presence or 
absence of different CS oligomers was carried out in a rat model. The hypoglycaemic effects 
of CS oligomers on drug absorption from pulmonary delivery were found to be stronger than 
that from the oral route.
38
 This finding suggests the superiority of pulmonary calcitonin 
delivery over the oral route. CS has also been reported to directly activate the immune system 
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due to its cationic nature
28
 when used as a vaccine adjuvant,
39
 suggesting potential 
applications in vaccine delivery. Studies on the lung delivery of CS based vaccines are 
described in section 4.5 of this review. Considering the above discussed background, it is 
clear that CS has profound applications as a promising pharmaceutical excipient
22
 in drug 
delivery.  
 
3. Toxicity of CS 
To date, the safety issues of CS and its derivatives in pulmonary drug delivery systems have 
not been fully understood. Currently, there are no published human toxicity data on CS NPs. 
Therefore, the potential adverse effects of CS NPs in humans remain unclear. Various human 
airway cell culture models, e.g., bronchial Calu-3 cells and alveolar A549 cells, have been 
used to investigate the safety and efficacy of inhaled therapeutics with CS-based carriers; 
however, contradictory outcomes have been reported.
1, 17, 40-42
 Recently, the toxicity of CS 
and leucine-conjugated CS (5, Fig. 2) NPs on BEAS 2B cells were studied. The conjugate 
and its NPs showed relatively more toxic and inflammatory effects than those of CS and its 
NPs. However, the level of toxicity was low (IC50 = 2 mg/mL following 48 h exposure) and 
thus 5 has potential utility for pulmonary drug delivery applications.
43
 
 
The kinetics and toxicity of hydrophobically modified (with 5-cholanic acid) glycol 
chitosan (6) NPs were investigated after intratracheal instillation of NPs to mice.
44
 The NPs 
were rapidly taken up into the systemic circulation and excreted via the urine 6 h after 
intratracheal instillation. The NPs distributed to several extrapulmonary organs at very low 
levels and induced transient neutrophilic pulmonary inflammation from 6 h to day 3 after 
instillation. Following intratracheal nebulization in mice, NPs of PLGA coated with CS 
showed better biodistribution and low toxicity compared with non-coated NPs.
45
 CS coated 
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PLGA did not induce a significant inflammatory response as evidenced by low levels of 
cytokine release. The particle surface charge due to CS influenced the transporting of NPs 
across the mucus layer for better biodistribution. In another study, human alveolar epithelial 
cells incubated with CS-coated PLGA NPs containing DNA showed more than 90% viability 
at all concentrations tested.
46
 CS based PLGA NPs also showed more than 80% 
cytocompatibility with alveolar epithelial cells up to a concentration of 1 mg/mL, which is 
similar to the outcome observed by Grenha et al.,
17
 which produced up to 80% viability with 
Calu-3 cells and A549 alveolar epithelial cells up to NP concentrations of 1 mg/mL. Thus, 
the above studies suggest CS-coated PLGA NPs are safe for lung delivery of drugs. Overall, 
these findings support the use of CS based NPs as pulmonary drug delivery vehicles due to 
their excellent biocompatibility, low pulmonary toxicity, and rapid elimination.  
 
It is difficult to simulate in vitro interactions of inhaled medicines with lungs cells. Therefore, 
whole animal models are required to assess the real toxicological effects of NPs.  The toxicity 
of CS was found to be dependent on molecular weight, DD, and concentration. At high DD 
the toxicity is related to the molecular weight and the concentration; however, it is 
biologically less effective and less related to the molecular weight at lower DD. Thus, it is not 
straightforward to draw conclusions in terms of safety and toxicity issues due to the different 
DD, molecular weight, solubility and different assay conditions employed across different 
studies. Therefore, vigorous studies are warranted to obtain a clearer picture about the safe 
application of CS and its derivatives for pulmonary drug delivery.  
 
4. Chitosan based lung drug delivery  
CS based micro- and nanoparticles for pulmonary drug delivery have improved the 
therapeutic effects of drugs by modifying drug bioavailability. Drug encapsulation in micro- 
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and nanoparticles leads to reduced drug toxicity
1, 43
 and prolonged biological half-life of 
drug. CS NPs prepared by cross-linking with tripolyphosphate (TPP);
47-51
 or glutaraldehyde
52-
54
 (7, Fig. 2) have been demonstrated to enhance mucoadhesiveness or cellular absorption 
upon lung delivery, as discussed in the introduction section. Sustained delivery of CS 
encapsulated insulin NPs 
49
 and terbutaline sulfate 
55
 from DPI formulations have also been 
studied.  CS based DPI formulations of beclomethasone dipropionate,
56
 clindamycin
57
 and 
salbutamol sulfate
57
  showed promising controlled release profiles.  A DPI formulation 
containing hydrophilic (terbutaline sulfate) and hydrophobic (beclomethasone dipropionate) 
drugs, CS (as a drug release modifier) and leucine (aerosolization enhancer) showed 
promising sustained release delivery of both drugs from a single formulation.
58
 Lung delivery 
of microencapsulated protein,
48, 49
 tobramycin,
7
 and methotrexate
59
 loaded CS NPs from DPI 
formulations have been investigated. CS has also been found to increase the stability of drug 
formulations for lung delivery from DPI.
12, 60-64
 
 
The above studies demonstrate the potential of CS for lung delivery of drugs. Based on the 
published literatures, the types of drugs investigated for lung delivery with CS or CS-
derivatives can be classified as antibacterial and antitubercular drugs, anti-asthmatic,  
proteins/peptides, anticancer drugs, genes (includes RNA-based therapeutics), vaccines and 
other drugs (see Figure 3), which further supports the wide applicability of CS in lung drug 
delivery.  The motivations for investigating antibacterial/antitubercular drugs for lung 
delivery could be due to the bactericidal effect of the CS itself, which is an additional 
advantage for lung delivery of CS based drug formulations. A comprehensive list of CS 
based lung drug delivery systems is presented in Table 1. The well-established fabrication 
methods for preparing various drug encapsulated CS nanoparticles (ionic cross-linking, 
coacervation/precipitation, emulsion/double emulsion cross-linking, and self-assembly) will 
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not be discussed in detail herein as they have been reviewed previously.
65-67
  The following 
sub-sections are dedicated to the pulmonary delivery of various categories of drug 
formulations investigated so far. 
 
4.1. Antibacterial/antitubercular drugs 
Antibacterial/antitubercular drugs are the largest class of drugs investigated for CS based 
pulmonary delivery (40%, Figure 3), partly because CS has bactericidal properties in its own 
right. Pulmonary delivery of levofloxacin against Pseudomonas aeruginosa using CS 
modified by grafting octanoyl chains onto the CS backbone (7) has been studied.
68
 The 
highly dispersible dry powders of drug with varying concentration of CS and octanoyl CS 8 
were prepared to study the effect of hydrophobic modification on aerosolization of the drug. 
Microparticles of 8 displayed mucoadhesive properties leading to increased drug residence 
time in the pulmonary mucus. An MTT assay performed on an A549 cell line indicated that 
the polymers and the formulations were non-cytotoxic. However, 8 showed a significantly 
lower minimum inhibitory concentration (MIC), 4-fold less than that of the commercially 
available CS, against P. aeruginosa. The reasons behind the lower MIC of 8 are unclear. In 
another study, spray dried levofloxacin loaded, glutaraldehyde-crosslinked CS (7) 
microspheres showed higher dispersibility and better antimicrobial properties against P. 
aeruginosa infections in cystic fibrosis compared with levofloxacilin alone
53
 and the dry 
powder form of this drug was considered as a better alternative to the solution formulation for 
inhalation.  
 
Using CS, a DPI formulation of ciprofloxacin (CFX) was investigated.
69
 Spray dried 
microparticles (MPs) displayed improved aerosolization properties and the encapsulated drug 
showed high antimicrobial activity against P. aeruginosa and Staphylococcus aureus. The CS 
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containing CFX showed better drug entrapment and longer dissolution times that led to 
prolonged release of drug from the MPs without significant toxic effects to lung epithelial 
cells. Lower cell viabilities caused by the MPs containing higher concentrations of CS were 
also noted; however, dextran containing CS particles were shown to be the least cytotoxic. 
 
Glutaraldehyde crosslinked CS (7) microspheres loaded with antitubercular drugs, ofloxacin 
52
 and moxifloxacin,
70
 have been investigated for pulmonary delivery.   The ofloxacin loaded 
CS microspheres induced cellular uptake and prolonged release of drug from the 
microspheres. It was concluded that the lung delivery of drug loaded CS microspheres from a 
DPI formulation could improve the delivery efficiency of drug to alveolar macrophages and 
thereby reduce the duration of tuberculosis treatment with the unmodified, orally delivered 
drug by at least 6 months.  With regards to the lung delivery of moxifloxacin, Ventura et al., 
prepared spray dried drug loaded glutaraldehyde crosslinked and non-crosslinked CS 
microspheres, which showed a significant initial burst release followed by a prolonged drug 
release from all crosslinked microspheres that contained the highest amount of 
glutaraldehyde in the formulation. Non-crosslinked microspheres rapidly swelled and 
released the dissolved free CS to interact with the cell by altering the biomembrane 
permeability; however, the crosslinked microspheres did not show this property. The 
crosslinking with glutaraldehyde was not required to retard absorption of drug through the 
pulmonary epithelium cells; however, significant prolonged release of drug was obtained 
from the crosslinked microspheres. Very recently, spray dried MPs of clarithromycin (a 
hydrophobic antibiotic) containing CS and leucine for pulmonary delivery from a DPI was 
reported.
71
 The MPs showed excellent dispersibility (fine particle fraction, FPF, = 73%) due 
to the presence of leucine in the formulation, and exhibited slow release of drug due to the 
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CS. The MPs did not induce toxicity on Calu-3 cells, indicating the safety of these particles 
for lung delivery.   
 
The DPI formulation of another antitubercular drug, ethambutol dihydrochloride (EDH) 
encapsulated in CS NPs produced lower toxicity, higher potency and better permeation than 
the pure drug particles.
72
 Three different cell lines i.e., A549, Calu-3, and NR8383 cells, were 
investigated and the cell viability of all of them showed promise. The CS coated EDH 
displayed a higher MIC (<1 μg/mL) compared with pure EDH (MIC 2 μg/mL) against 
Mycobacterium bovis and the CS contributed to the antimicrobial activities along with the 
EDH.  The prepared DPI formulation of CS loaded EDH showed a sustained release of drug, 
suggesting that it could help to minimize the duration of treatment and the risk of developing 
multidrug resistance against tuberculosis compared to that of pure EDH. Spray dried 
inhalable powders containing isoniazid-loaded CS NPs showed sustained delivery of the drug 
to the lung.
73
 An in vitro drug release study showed that the rate of isoniazid release from 
NPs was dependent on the amount of CS used in the formulation i.e., the drug released was 
decreased by increasing the CS concentration in the formulation, which indicted the 
prolonged release of drug from the NPs.  
 
Among the antitubercular drugs, rifampicin has been the most extensively investigated for 
lung delivery. Nebulized rifampicin-loaded CS coated liposomes were found to show better 
mucoadhesive properties and lower toxicity (against A549 epithelial cells) compared with 
non-coated ones.
74
 Using this drug, the development of MPs for drug delivery to the lungs 
from a DPI formulation by coating liposomes with CS-xanthan gum (XG) polyelectrolyte 
complexes, known as chitosomes, was also investigated.
75
  Using a mixture of soy 
phosphatidylcholine and hydrogenated soy phosphatidylcholine in two different 
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concentrations, two groups of liposomes were prepared to encapsulate appropriate amounts of 
rifampicin. The obtained vesicles were then coated with different CS-XG weight ratios to 
prepare the desired liposomes and chitosomes. The nebulization and rheological properties of 
chitosomes were affected by the CS-XG weight ratio in the formulation. It was concluded 
that the CS-XG weight ratio of 1:0.5 (w/w) coating was able to greatly improve drug 
deposition (FPF = 37.8%) in comparison with the corresponding uncoated liposomes (FPF = 
13%). The reason behind this has not been clearly demonstrated; however, it was suggested 
that the coating of liposomes with a polyelectrolyte complex at an appropriate ratio improved 
liposome resistance to aerosolization, which suggests that the CS has an impact on drug 
dispersion from DPI formulations. Recently, Garg et al.
76
 demonstrated the application of 
spray dried inhalable CS NPs for sustained delivery of isoniazid and rifampicin. After 
administration, both drugs were detected in various organs (lungs, liver, spleen and kidney) 
until 24 hours post nebulization.  It was concluded that the chemotherapeutic efficacy of a 
single dose of drug-loaded CS NPs was more effective against mycobacteria than the free 
drugs. Using rifampicin and isoniazid, spray dried CS based MPs with other excipients have 
also been investigated.
29
 CS, guar gum, mannose and guar gum coated-CS were used for 
encapsulating the drugs. Guar gum containing spray dried particles showed a uniform size 
distribution with a smooth surface compared with mannose formulations; however, CS 
containing formulations exhibited the best surface morphology among the formulations, 
which could be related to the better mechanical strength of preformed CS NPs that resist 
particle squeezing during flash evaporation in the spray drying process. The drug release 
showed a biphasic pattern of release, i.e., an initial burst followed by a sustained release 
pattern due to the presence of CS in the formulation. An in vivo lung (mouse model) 
distribution study showed that the guar gum coated chitosan (GCS) formulations had a 
prolonged residence time at the target site and thereby improved the therapeutic application 
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of drug with a significant reduction in systemic toxicity. The drug loaded GCS formulation 
resulted in almost 5-fold reduction of the number of bacilli compared with the control group. 
The preferential uptake of GCS NPs indicated the selective uptake capability of the mannose 
moieties present in guar gum to the specific cell surface of macrophages and that was an 
additional advantage in using guar gum in the formulation. It was concluded that the dual 
targeting DPI formulation containing GCS NPs could be a promising carrier for selective 
delivery of antitubercular drugs for efficient management of tuberculosis as well as other 
lung infections.  
 
CS based rifampicin along with another potential antitubercular drug, rifabutin, was also 
investigated by Rohan et al.
60
 Rifampicin and rifabutin loaded CS microsphere based DPI 
formulation systems were developed for the treatment of tuberculosis. An in vitro drug 
release study in simulated lung fluid (pH 7.4) showed a sustained release for 12 and 96 hours, 
respectively, for rifampicin and rifabutin microspheres, respectively. The drug release was 
dependent on both swelling of CS and the solubility of the drugs in the dissolution medium. 
The MPs were found to be taken up by a human macrophage cell line (U937), thus enabling 
targeting of M. tuberculosis. An in vivo acute toxicity study in rats revealed no significant 
local adverse effects. It was concluded that the MPs could be useful for developing an 
improved, targeted, and efficient system for the treatment of tuberculosis; however, extensive 
toxicological studies for repeated dose inhalation of these drugs is required to better assess 
their long term safety for pulmonary delivery. 
 
Lung delivery of tobramycin embedded in PLGA NPs modified by CS to impart the desired 
surface property (i.e., positive charge) was investigated.
7
 Initially, the PLGA based NPs were 
prepared and later coated with CS to obtain particles with the desired surface charge, 
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mucoadhesiveness, particle size and drug release properties.  The surface of NPs of PLGA 
modified by positively charged CS showed a higher interaction with mucin compared to 
those of unmodified PLGA and PVA coated NPs. Therefore the adsorption of mucin onto the 
surface of CS modified PLGA NPs by shielding of NPs surface charge, was the dominant 
factor in the facilitated transport of NPs. Oritz et al.
77
 developed dapsone-loaded CS 
microcapsules for deep lung delivery against Pneumocystis carinii pneumonia (PCP). The 
developed particles showed promising in vitro dispersion (FPF = 50%) and sustained drug 
release from the NPs.  The particles were deposited into the deep lungs, and bronchioalveolar 
lavage fluid (BALF) analysis showed low cytotoxicity of the CS encapsulated drug compared 
with free drug. It was suggested that pulmonary administration of the drug loaded CS 
particles could be considered an effective and promising alternative for PCP treatment. Using 
CS as a carrier, clindamycin, a lincosamide antibiotic, was studied for in vitro lung delivery.
57
 
A DPI formulation of clindamycin hydrochloride loaded CS microspheres (particle size 1.7-
1.8 μm) was prepared by spray drying and blended with a large lactose carrier (Inhalac 250). 
The formulation showed good flow properties due to the large carrier and prolonged 
clindamycin release occurred due to the presence of CS in the formulation.  
 
Very recently, a CS based formulation of gentamicin, a widely used aminoglycoside 
antibiotic, was investigated for lung delivery with dual antimicrobial and antioxidant 
activity.
78
 Due to the promising antioxidant
79
 properties of fucoidan (a sulfated 
polysaccharide from seaweed) to scavenge the reactive oxygen species generated by 
gentamicin during treatment, Huang et al., used fucoidan with CS (CSF) to generate 
gentamicin encapsulated NPs and to study the prolonged release of gentamicin. The various 
electrostatic interactions between the negatively charged fucoidan and the positively charged 
CS and gentamicin enabled CSF NPs to encapsulate the drug efficiently. The cumulative 
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concentration of the released drug indicated that almost 99% of the drug was released from 
CSF NPs in 72 hours. The intratracheal administration of drug-loaded CS/F NPs delayed the 
time to reach Cmax in plasma, thereby reduced the risk of systemic toxicity caused by high 
gentamicin concentration in plasma. It was concluded that the intratracheal administration of 
gentamicin loaded CSF NPs into rat lungs improved antimicrobial efficacy with reduced 
systemic toxicity caused by high doses of intravenously injected gentamicin. The 
encouraging results from this study indicate that CSF based lung delivery of gentamicin 
shows promise for the treatment of pneumonia. 
 
4.2. Proteins/peptides 
As protein/peptides are susceptible to degradation by digestive enzymes after oral 
administration, lung delivery has been considered to be a more suitable delivery route. 
Therefore, proteins/peptides were the second most common drug class investigated for CS 
based lung drug delivery (Fig. 3, Table 1).  
 
Using CS as a carrier, insulin has been investigated for pulmonary delivery.
48, 61, 62, 80
 Yan et 
al. studied the absorption enhancing effects of CS NPs with various molecular weights on the 
pulmonary absorption of insulin in rats.
80
 CS NPs with small size and surface properties i.e., 
positive zeta potential, were useful carriers for improving the pulmonary absorption of 
peptides and proteins. The surface positive zeta potential was considered to be the major 
contributing factor for the prolonged retention of drugs in lung tissues and penetration into 
the mucus layer. The absorption enhancing effects of CS NPs was dependent on the DD of 
CS. CS NPs with MWs from 35 to 168 kDa were found to be safe carriers for improving the 
pulmonary absorption of insulin without damaging lung tissues. Using a rat model, deep lung 
delivery of microencapsulated insulin-loaded CS NPs was shown to induce more pronounced 
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and prolonged hypoglycemic effects compared with pure drug.
48
 In another study,
80
 
pulmonary delivery of insulin loaded CS NPs, with a small size and marked cationic charge 
was shown to improve the absorption of insulin. This was due to prolonged retention of NPs 
in lung tissue and penetration into the mucus layer without significant membrane damage to 
the lung tissues. It was suggested that the absorption enhancing effect of the NPs was affected 
by the DD of CS and was independent of the molecular weight. In addition, the CS NPs were 
found to have low toxicity.  The lung delivery of insulin using CS modified PLGA 
nanospheres was also investigated
13
 and it was shown that the NPs were eliminated from the 
lungs more slowly compared with unmodified PLGA NPs due to their mucoadhesive 
properties. This further supports the applicability of CS in lung drug delivery for controlled 
release. The in vitro delivery of dry powders of insulin containing CS prepared by spray 
drying showed promising dispersibility (FPF = 46%) with sustained insulin release over 60 
hours.
61
 Insulin loaded N-trimethyl CS (2) microspheres produced by a supercritical fluid 
technique also showed promising results.
62
 The particle characteristics were maintained and 
the insulin structure was largely preserved in the microspheres even after storing the powders 
at 4°C for one year. However, no in vivo studies have been carried out. 
 
The surface modification of CS and glycol CS (3) NPs with the surfactant Lipoid S100 for 
the pulmonary delivery of low molecular weight heparin (LMWH) has been investigated in a 
mouse model. 
51
 The administration of the surface modified NPs resulted in an increase in the 
systemic coagulation time, indicating that the NPs are promising carriers for pulmonary 
delivery of LMWH. Murata et al.
32
 studied the lung delivery of elcatonin loaded in liposomes 
which were coated with low molecular weight CS oligosaccharide (oligo CS, MW~1000) and 
polyvinyl alcohol with a hydrophobic anchor (PVA-R) as a surface modifier. The PVA-R 
modification reduced interaction with A549 cells, whereas oligo-CS modification 
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electrostatically enhanced cellular interaction and thereby the therapeutic efficacy of 
elcatonin after pulmonary administration to rats was significantly enhanced and prolonged for 
48 h. It was emphasised that the CS-modified liposomes adhered to lung tissues and caused 
opening of tight junctions, which enhanced the absorption of the drug. This study showed the 
superiority of oligo-CS over PVA in modifying drug loaded liposome NP surfaces for 
effective peptide drug delivery through the pulmonary route.  
 
The lung delivery of insulin using CS modified PLGA nanospheres was investigated
13
 and it 
was shown that the nanospheres were eliminated from the lungs more slowly compared with 
unmodified PLGA nanospheres due to their mucoadhesive properties. This further supports 
the applicability of CS in lung drug delivery for controlled release. The CS-modified PLGA 
nanocomposite particles exhibited enhanced pulmonary absorption of salmon calcitonin 
compared with non-modified PLGA nanocomposite particles via the lung delivery from a dry 
powder formulation.
8
 The release and absorption of the salmon calcitonin encapsulated 
PLGA NPs coated with CS was controlled by the mucoadhesion and absorption enhancing 
effects of CS.
8
 More than 40% of the CS modified PLGA NPs remained in the lungs 4 h after 
intratracheal administration into rat lungs. In another study, lung delivery of CS coated 
PLGA NPs containing palmitic acid-modified extendin-4 (Pal-Ex4) was investigated.
31
 
Promising outcomes such as higher absorption and delayed release of drug from the NPs 
were observed.  Moreover, CS-coated PLGA NPs remained in the lungs for ∼72 h, whereas 
most of the unmodified PLGA NPs had disappeared 8 h after administration. It is noteworthy 
that the hypoglycemic efficacy of inhaled CS coated Pal-Ex4 PLGA NPs was 3.1-fold greater 
than that of unmodified NPs.      
 
4.3. Anticancer drugs 
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The use of CS as a surface modifier for lung delivery of anticancer drugs has not been 
extensively explored compared with other drug classes (only 17%, Fig. 3). CS-modified 
PLGA NPs containing paclitaxel delivered into rat lungs showed significantly increased 
uptake and cytotoxicity against a lung cancer cell line (A549). 
81
  A lung-specific increase in 
the distribution of paclitaxel was observed for CS-modified NPs compared with unmodified 
drug. It was not fully clear why the lung specifically accumulated the drug; however, the 
formation of large NP agglomerates in contact with plasma proteins during circulation, 
followed by enhanced entrapment of the formed agglomerates by the lung capillaries, was 
thought to be the cause. In addition, it was also demonstrated that the electrostatic interaction 
between the positively charged NP surfaces due to CS coating and negatively charged 
endothelium of lung tumour vasculature was also responsible for the lung-specific drug 
accumulation. This is an encouraging result for delivery of drug into the target organ for the 
treatment of lung cancer. Recently, docetaxel-loaded CS microspheres, prepared by 
glutaraldehyde crosslinking (7) were shown to release the drug to a maximum extent in the 
target tissue i.e., lung, confirmed by in vivo studies in a mouse model. In vitro release 
indicated that the CS coated drug microspheres had a well-sustained release profile (70% 
drug released in 19 days). 
54
 Using CS coating technology, lung delivery of CS-coated PLGA 
NPs containing 2-methoxyestradiol (2-ME) showed good dispersibility, high respirable 
fraction and a sustained release profile.
59
 It was shown that the NPs were suitable for lung 
delivery and significantly enhanced cytotoxicity of 2-ME without noticeable inflammation in 
rat lungs, suggesting that inhaled 2-ME CS NPs have great potential for targeted, highly 
effective and safe treatment of lung cancer.  
 
Cisplatin, another widely used anticancer drug has been investigated for lung delivery.
12, 82
 
Positively charged CS coated cisplatin micro/NPs showed cytotoxicity similar to or lower 
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than that of the pure drug on P388 murine and A2780 human cells. The NPs with the smallest 
size and the lowest positive zeta potential due to the surface CS showed more activity than 
that of uncoated cisplatin on A549 human cells. Singh et al. 
12
 studied the lung delivery of CS 
coated cisplatin and achieved better efficacy against lung cancer by using CS coated cisplatin 
microspheres compared with the drug alone. The lung delivery helped localize the drug in the 
lungs, and provided sustained action. The drug release from CS microspheres showed a 
biphasic pattern with an initial burst effect, followed by a subsequent slow release. Cisplatin 
loaded CS microspheres showed higher cytotoxic effects on A549 human lung cancer cells 
and a higher IC50 value compared with the free drug. Additionally, the drug loaded CS 
microparticulate DPI system was stable for 6 months at 25°/60% RH and at 40°/75% RH, 
without significant changes in drug content, except reducing the FPF.   
 
4.4. Anti-asthmatic drugs 
Inhaled formulations of anti-asthmatic drugs have been proven clinically effective and 
several drugs in DPI or pMDI (pressurized metered dose inhaler) forms are available on the 
market. CS based formulations of anti-asthmatic drugs are yet to be approved for lung 
delivery; however, some drugs such as salbutamol sulfate,
57, 83
 theophylline,
18
 terbutaline 
sulfate and beclomethasone dipropionate
30
 have been investigated for sustained release 
delivery from CS based nano/microparticles. 
 
The most useful and available anti-asthmatic drug, salbutamol sulfate, has been formulated 
using CS for sustained release delivery.
83
 The spray dried CS-salbutamol sulfate 
microparticles showed increased deposition in the target sites with FPF of 55%-65%, which 
is much higher than that of large, lactose carrier-based formulations (FPF 11.2%). 
Additionally, the CS based salbutamol sulfate produced sustained release of drug from the 
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microspheres. It was suggested that the CS-modified spray-dried powders not only enhanced 
the dispersibility and lung deposition, but also produced prolonged release of drug; however, 
the mechanism of how CS enhances the dispersibility was not demonstrated. Prior to this 
study, Kamble et al. used the same salbutamol sulfate-encapsulated CS microspheres for 
inhalation purposes.
57
  The CS microspheres were prepared by spray drying with or without a 
crosslinking agent, citric acid. The microspheres showed excellent flow properties and the 
crosslinking agent was found to decrease the entrapment efficiency and in vitro sustained 
release of drug. This effect might be due to the reduction in swelling ability of the CS in the 
microspheres because of the high concentration of citric acid increasing the rigidity of 
microspheres.  Recently, Zhang et al. studied the DPI formulation of CS based theophylline.
18
 
Microspheres were prepared by spray drying theophylline, carboxymethyl CS (4) and β-
cyclodextrin, which produced irregular spherical shapes with or without smooth surfaces. In 
addition, the cytotoxicity of the microspheres was concentration dependent and no toxicity to 
liver, kidneys or haemoglobin was observed at low concentrations (<0.1172 mg/mL). An in 
vivo implant experiment in Sprague-Dawley rats demonstrated that the particles were 
biocompatible.  
 
CS based sustained release delivery of beclomethasone dipropionate
55
 and terbutaline sulfate 
58
 from DPI formulations have also been investigated.  Using different molecular weights of 
CS (separately or different combinations), the spray dried microparticles of hydrophobic drug 
beclomethasone dipropionate 
55
 were prepared. With increasing molecular weight of CS, the 
FPF of drug decreased; however, the time for 100% drug release was increased. The same 
research group later studied the sustained release of the combination of hydrophilic 
(terbutaline sulfate) and hydrophobic (beclomethasone dipropionate) drugs from CS based 
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microparticles for pulmonary delivery. Increased CS molecular weight was associated with 
increased duration of drug release i.e., favoured sustained release of drugs.  
 
Large porous particles have a significant effect on the lung delivery of drugs
84
 and 
intratracheal delivery (in rat) of porous particles of CS containing budesonide from a DPI 
formulation prepared by spray drying, showed an extended half-life compared with a 
conventional formulation and with a fourfold improvement in local and systemic 
bioavailability. Similar anti-inflammatory activity of budesonide and developed formulations 
has been observed.
85
 Improved aerosolization efficiency was also reported with PLGA and 
soy lecithin (PC) NPs (PLGA-PC) from a DPI formulation containing large porous particles 
of CS microparticles crosslinked with TPP and dextran sulfate DXT).
86
 The prepared porous 
CS carrier particles (CS-TPP-DXT) exhibited desired aerosolization characteristics and 
physicochemical robustness due to their electrostatic properties. Due to the high negative 
charge, the carrier particles were limited to adsorb only cationic nanoparticles, which was the 
drawback of the prepared carrier.   
 
 
4.5 Other drugs 
A DPI formulation of itraconazole loaded CS NPs crosslinked with TPP has also been 
reported. 
87
 A CS based DPI formulation of carvedilol containing poly(ethylene-co-vinyl 
acetate) (PEVA) NPs coated with CS for lung delivery has been investigated. 
88
 The NPs 
were spray dried with lactose or mannitol as carriers. The results revealed that a high amount 
of PEVA NPs was associated with mucin, confirming the enhanced mucoadhesion of NPs 
coated with CS compared with that of uncoated NPs. The in vitro aerosolization behaviour 
Page 21 of 49 Nanoscale
N
an
os
ca
le
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
08
 Ju
ly
 2
01
6.
 D
ow
nl
oa
de
d 
by
 Q
ue
en
sla
nd
 U
niv
ers
ity
 of
 T
ec
hn
olo
gy
 on
 08
/07
/20
16
 04
:28
:15
. 
View Article Online
DOI: 10.1039/C6NR03256G
22 
 
indicated that the mannitol-based formulation was found to have better flow properties and 
higher FPF. 
 
Recently, Yang et al. 
89
 extended the application of CS and CS-oligo to a DPI formulation of 
fanhuncaoin, a newly discovered anti-inflammatory drug isolated from a Chinese herb. Both 
CS and CS-oligosaccharide showed excellent dispersibility enhancement of the spray dried 
inhalable powder. Powder formulations without CS led to the poorest flowability and the 
formed particles appeared fused with each other. It was suggested that CS modified the 
surface of the powder particles and contributed to decreased interparticulate cohesion forces 
and thereby improved powder dispersibility.  
 
4.6. Genes/nucleotides  
Pulmonary delivery of genes/peptide has become an emerging are of research a list of 
investigated genes/nucleotides has been presented in Table 2. Lung delivery of plasmid DNA 
(pDNA) from a DPI formulation has been studied.
90
 Spray dried pDNA containing CS and its 
soluble derivative N-trimethyl CS (2) were prepared. Formulations of both CS and 2 showed 
significantly greater emitted dose (> 90%) and in vitro pulmonary deposition (FPF > 35%) of 
dry powder dispersions compared with powders without CS (emitted dose 57%; FPF 12%).  
Both CS and 2 enhanced the level of reporter gene expression to human lung carcinoma cells.  
 
Using a supercritical fluid technique, dry powders of CS-pDNA complexes were prepared for 
lung delivery. 
91, 92
 In vivo pulmonary transfection studies in mice indicated that the powders 
had higher transfection potency than the aqueous solutions containing the same amount of 
DNA. The removal of CS from the formulation led to extensive degradation of DNA during 
manufacturing and storage. Therefore, it was concluded that the CS improved the stability of 
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pDNA powder during manufacturing and storage of the formulations.
63
 CS and CS coated 
PLGA NPs containing BSA and DNA showed highest burst release (43%) within two days 
and more than 80% sustained release in 3 weeks; however, CS-PLGA NPs were more stable 
(5 days at 37ºC) than that of CS NPs.
46
    
 
Okamoto et al. 
93
 studied CS-β-interferon gene complex (pCMV-Muβ) powders as a non-
viral vector for intratracheal administration to compare their gene expression and therapeutic 
efficacy using mice burdened with pulmonary metastases. A luciferase expression system 
revealed that the genes expressed in both normal and tumorous tissues and the intratracheal 
powder resulted in higher expression than the intravenous or intratracheal solution 
formulations. The intratracheal administration of powder pCMV-Muβ at a dose of 1 μg 
significantly extended the mean survival time compared with untreated control. The results of 
this study indicated a superior therapeutic effect of CS/pCMV-Muβ powders against a murine 
model of lung metastasis with respect to the untreated drug. It was concluded that therapeutic 
gene powders for pulmonary delivery are promising for gene therapy to treat lung cancer. 
Although the effects of CS in the formulation are not fully clear; it did improve the stability 
of the powder formulation.   
 
Stable CS NPs encapsulating siRNA were prepared using an ionic crosslinking technique for 
lung delivery and were found as suitable carriers for delivery of siRNA using a jet nebuliser. 
94
 Very recently, Jeong et al. 
95
 also found promising activity in terms of cellular uptake and 
gene silencing of CS based siRNA NPs after intratracheal administration in a mouse model.  
Intratracheal administration of CS-coated PLGA based nanoplexes with antisense 2'-O-Me 
RNA (OMR), showed higher cellular OMR uptake compared with OMR alone.
96
 The results 
showed no remarkable changes in lung physiological parameters after lung delivery of this 
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drug and suggested appreciable local tolerability of the OMR-nanoplex formulation. Here CS 
facilitated intracellular uptake of the OMR-nanoplex.  Regnstroem et al., studied the gene 
expression profiles of CS alone or CS formulated luciferase reporter plasmid (CS-pLuc) in 
pulmonary delivery (intratracheal administration) in mouse lungs.
97
  CS-pLuc was found to 
upregulate genes that protect the cell from oxidative stress and inflammation, such as heme 
oxygenase-1 and catalase. In addition, CS-pLuc activated genes involved in reaction to stress, 
such as DNA damage repair.  
 
4.7.Vaccines  
Administration of a vaccine to the lungs avoids the use of needles, as many people suffer 
from injection phobia. Furthermore, pulmonary vaccination also induces a mucosal immune 
response in addition to the systemic immune response obtained by injection. Such a local 
response may increase the effectiveness of vaccination against pathogens. Lung delivery of 
vaccines has been studied for decades; however, no pulmonary vaccine products are 
commercially available as yet. Although lung delivery of vaccines is not yet established, 
large numbers of vaccine delivery formulations (Table 3) have been investigated.
98-100
 In 
vaccine formulation, CS has been used as an adjuvant due to its nontoxic and mucoadhesive 
properties and it has been found to boost antibody responses to intranasal delivered influenza 
vaccine dry powder formulations.
41
 CS has also been reported to directly activate the immune 
system due to its cationic nature
28
 when used as a vaccine adjuvant. CS-derived polymer NPs 
protected DNA vaccines against degradation by DNAse, resulting in enhanced 
immunogenicity of a DNA vaccine against hepatitis B virus.
101
  The CS derivatives 9-11 
were prepared, respectively, via ammonium persulfate-initiated free radical polymerization 
with methylmethacrylate, N-trimethylammoniumethylmethacrylate, and N-
dimethylammoniumethylmethacrylate as monomers, respectively.  
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The lung delivery of DNA vaccines against tuberculosis was found to be advantageous 
compared with intra muscle immunization, and the increased immunogenicity was achieved 
by delivery of this DNA encapsulated in CS NPs.
27
 Using an HLA-A2 transgenic mouse 
model, the pulmonary delivery of DNA plasmid encoding eight HLA-A*0201-restricted T-
cell epitopes from M. tuberculosis formulated in CS NPs was studied.
27
 Lung delivery of the 
DNA plasmid incorporated in CS NPs was found to induce increased levels of IFN-γ 
secretion compared with pulmonary delivery of plasmid in solution for intramuscular 
immunization. Pulmonary delivery of CS complexed with M. tuberculosis DNA vaccine 
(mut-T-epitope DNA vaccine, pHSP65pep) enhanced the mucosal immunity.
102
 CS was 
found to significantly increase pulmonary CD4+ IFN-γ+ and CD8+ IFN-γ+ T cell frequency 
induced by pHSP65 pep, which was much higher than that of the splenic counterpart. The 
CS-pHSP65pep complex produced better protection compared with the vaccine without CS.  
 
Recently, the uptake and immune response of adjuvant Pam3Cys (Toll-like receptor-1/2 
agonist) coupled with CS-DNA NPs were explored by using a three-dimensional human 
epithelial cell culture model.
103
  CS-based DNA NPs delivery into lung cells was shown to 
induce antigen-specific immunity. In addition, the Pam3Cys adjuvanted CS-DNA NPs 
significantly enhanced the Th1 associated immune response due to elevated IL-8 and TNF-α 
levels. The overall results were promising for pulmonary DNA vaccination against 
intracellular pathogens (M. tuberculosis or influenza virus). Amidi et al.
104
 studied the 
potential of N-trimethyl CS (2) microparticles for pulmonary delivery of diphtheria toxoid 
(DT). The pulmonary immunization with DT-loadedmicroparticles of 2, prepared by 
supercritical fluid extraction, showed a strong immunological response reflected by inducing 
IgM, IgG, IgG subclasses (IgG1 and IgG2) antibody levels as well as neutralizing antibody 
titers comparable to, or significantly higher than, those observed after subcutaneous 
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administration of conventional alum-adsorbed DT antigen. In addition, CS based DT 
microparticles induced detectable pulmonary secretory IgA levels. It was concluded that the 
pulmonary delivery of CS based DT microparticles is a potent new delivery system against 
diphtheria.  
 
4.8 . Chitosan derivatives and pulmonary drug delivery 
With a view to achieving better physicochemical properties (i.e., improved solubility), low 
toxicity and improved biodegradability, various types of chemical modifications in CS 
structure have been studied. The applicability of chemically modified CS/ CS derivatives for 
lung delivery of different drugs is discussed below.  
 
Very recently, gentamicin (GM) encapsulated CS/fucoidan NPs, as demonstrated in Fig.4, for 
lung delivery against Klebsiella pneumoniae were developed 
78
 and intratracheal 
administration of drug loaded CS/fucoidan NPs in rats presented a superior antimicrobial 
efficacy with eliminated systemic toxicity. It was demonstrated that the CS contributed the 
first line antimicrobial function before releasing sufficient amount of drug from the NPs and 
thus exerted a synergistic antimicrobial effect. However, the contributions of fucoidan to the 
NPs physicochemical properties, dispersibility, drug release from NPs and antimicrobial 
activities were not addressed. 
 
TPP crosslinked CS NPs with added PEG 1000 were prepared for lung delivery from 
pMDIs.
50
 PEG was used in the formation of NPs as it acts as a polymeric surfactant that helps 
reduce the cohesive interactive forces among particles suspended in a suitable solvent. Due to 
the presence of CS, particles were positively charged and non-aggregated at the pH of the 
airways. Crosslinked CS-PEG 1000 NPs showed greatest dispersibility and physical stability 
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in HFA-227 due to the positive charge of CS. The results demonstrated the superiority in 
terms of stability of CS based NPs in pMDI formulations compared with that of formulations 
without CS. Makhlof et al. 
34
 coupled glycol CS (3) with thioglycolic acid mediated by the 
water-soluble carbodiimide EDAC to give conjugate 12 and evaluated it for the pulmonary 
delivery of peptide calcitonin. Drug loaded NPs of 3 and 12 were prepared by an ionic 
gelation technique.  Following intratracheal administration to rat lungs, NPs of 12 showed a 
two-fold increase in mucoadhesion to lung tissue compared with non-thiolated NPs. 
Calcitonin-loaded NPs of 3 and 12 resulted in a prolonging of the hypocalcemic effect for at 
least 12 and 24 hours, respectively. A pulmonary toxicity assay revealed the biocompatibility 
of the NP formulations with lung tissue. These findings suggest that both 3 and its thiolated 
derivative 12 are promising and safe carriers for pulmonary delivery of peptide drugs such as 
calcitonin. Spray dried levofloxacin encapsulated in hydrophobically modified CS with 
octanoyl groups (8) was found to enhance dispersibility of drug from a DPI formulation 
68
. In 
vitro cytotoxicity evaluation using the MTT assay performed on the A549 cell line confirmed 
that the formulations were non-cytotoxic. The modified CS showed significantly lower MIC 
(4-fold) than that of commercially available CS against P. aeruginosa. Drug loaded modified 
CS microparticles showed higher FPF (52%) compared to that of non-modified CS (FPF 
20%) and thus 8 was considered a highly efficient dispersibility enhancer for use in the DPI 
formulation. 
 
Jin et al. 
105
 synthesised a urocanic acid conjugate of CS (13) via EDAC mediated coupling, 
which was complexed with the protein PTEN (phosphatase and tensin homolog deleted on 
chromosome 10) and delivered to the lungs of K-ras
LAI
 mice through a nose-only inhalation 
system. The 13- PTEN complex significantly suppressed the development of lung tumor 
through the formation of a nuclear complex between PTEN and p53, by suppressing Akt-
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related signals as well as cell cycle regulation. It was suggested that 13 is a promising aerosol 
delivery vehicle with little toxicity and enhanced gene transfection efficiency and 13-
mediated PTEN delivery may be compatible with non-invasive in vivo gene therapy for 
prevention and treatment of lung cancer. Luo et al.
106
 reported the application of a 
guanidinylated CS-salbutamol conjugate (14) as a carrier for lung delivery of siRNA 
targeting the β2-adrenoceptor. CS was firstly coupled with salbutamol, a β2-adrenoceptor 
agonist, in the presence of epichlorohydrin and the resulting product was then guanidinylated 
with aminoiminomethanesulfonic acid increase non-specific cellular uptake. The final 
conjugate 14 was substituted with approximately 3.5% salbutamol and 8.2% guanidino 
groups. Conjugate 14 facilitated targeted gene delivery into the mouse lungsand was shown 
to decrease the cytotoxicity against HEK293 cells and enhance gene-silencing efficiency 
compared with CS.  It was thus suggested that 14 is a promising carrier for siRNA delivery 
for the treatment of viral respiratory infections.  
 
Very recently, Jeong et al.
95
 synthesised cell-penetrating peptide -modified CSs (15-17) by 
conjugating a peptide consisting of nine arginine units (R9) and a variable spacer arm of 
glycine units (Gn) via the C-terminal carboxylate to the amine of CS via the carbodiimide 
method. The degree of substitution was quite low due to the poor solubility of the R9Gn 
peptides, with only an average of two peptides conjugated per CS molecule. The conjugates 
were complexed with siRNA to investigate cellular uptake and gene silencing. In a mouse 
model, intratracheal administration of NPs revealed that the conjugate with the longer spacer 
arm (17, R9G10) was more effective in delivering genes compared with unmodified CS.  
 
El-Sherbiny and Smyth
107
grafted mPEG5000 onto both CS (PEG-g-CS, 18) and its N-
phthaloyl derivative (PEG-g-NPHCS, 19) via EDAC-mediated coupling and prepared 
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swellable microparticles using a cryomilling process to investigate the suitability for lung 
delivery of a model drug, sodium fluorescein.  The drug loaded microspheres of 19 showed 
higher values of cumulative drug release compared with microspheres of 18. The reason 
behind this behaviour was the presence of the hydrophobic phthaloyl group in 19 which 
retarded the entrance of fluid into the matrix and consequently led to the slow release of drug.  
Subsequently copolymer 19 was self-assembled into bovine serum albumin (BSA)-loaded 
NPs. The NPs were encapsulated in respirable sodium alginate semi-interpenetrating 
polymeric network (IPN) hydrogel microspheres, prepared by spray drying, for controlled 
release pulmonary drug delivery. The FPF obtained was 31.5% with a slow sustained release 
of BSA up to 4 days.  The enzymatic degradation of microparticles in 0.2 mg/mL lysozyme 
occurred within the first 2 hours; however, the rate of degradation was reduced with 
increasing percentage of 19 in the microsphere. The results from both studies suggest that the 
microspheres of synthesised PEG grafted copolymer with CS could be suitable for inhalation 
and drug delivery to the deep lungs. These encouraging outcomes inspired El-Sherbiny and 
Smyth
108
 to use 19 for lung delivery of a widely used antibiotic, ciprofloxacin. Ciprofloxacin-
loaded and blank self-assembled NPs were prepared using a sonication technique and later 
the NPs were encapsulated into respirable alginate micro hydrogel particles (Fig. 5) and 
intratracheally delivered into rats by insufflation. The swellable particles showed lower 
ciprofloxacin levels in plasma compared with the control group (a mixture of large carrier 
lactose with micronized ciprofloxacin); however, produced higher drug concentration in lung 
for more than 7 hours, which is indicative of prolonged drug release from the formulation.   
 
Recently, Berezin and Skorik
109
 conjugated CS with isoniazid via two different methods. 
Firstly, CS was reacted with either epichlorohydrin or acrylic acid and the resulting products 
were coupled with isoniazid to give conjugates 20 and 22. The acrylic acid method was 
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preferred because it gave a higher degree of isoniazid substitution (up to 0.39). Due to their 
poor water solubility, 20 and 22 were phosphorylated to give conjugates 21 and 23. The 
conjugates were found to show high biocompatibility and relatively low toxicity.
109
 The in 
vitro antitubercular activity of the conjugates against M. tuberculosis H37Rv was lower 
compared with unmodified drug. It was suggested that the decrease in antitubercular activity 
was probably caused by limited availability of the bound drug for the antimicrobial action or 
incomplete cleavage of the strong C-N bond between drug and CS. The authors did not 
investigate the impact of the lung delivery of the synthesised conjugate. Very recently, the 
potential of a water-soluble CS-leucine conjugate (5), as a matrix for enhancing the 
dispersibility of NPs from a nanoparticulate DPI formulation was demonstrated.
11
 The 
surface hydrophobicity achieved by the hydrophobic domain of leucine (Fig. 6 A) and 
glutaraldehyde crosslinks formed on the NP surface was found to contribute to the enhanced 
dispersion (Fig. 6 C; FPD 0.31 mg) of the conjugated CS NPs. The promising rapid and 
prolonged drug release (Fig. 6 B) from leucine-conjugated NPs was associated with the 
nature of the cross-links as well as the amide groups that provided H-bonding with water thus 
influenced the drug release by swelling the nanoparticles. Previously, the low toxicity of the 
conjugate NPs for pulmonary delivery was demonstrated.
43
   
 
Conclusions and future directions 
Research in developing CS based lung drug delivery is progressing and has achieved 
considerable success so far. CS is universally recognised as a non-toxic, biocompatible and 
biodegradable polymer and has advantages over other biodegradable polymers as it is 
mucoadhesive, an absorption and dispersibility enhancer, immunogenic, and can encapsulate 
both hydrophilic and hydrophobic therapeutic agents. In this review, the advances in 
developing CS based inhaled formulations of various drugs investigated so far have been 
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reviewed. Due to the enhanced drug delivery efficiency, reduced unwanted adverse effects, 
increased solubility, improved surface hydrophilicity/hydrophobicity to encapsulate various 
drugs, and prolonged drug release, the conjugates of CS with drugs or other excipients, 
showed significant potential for extensive investigation for clinical applications. Appropriate 
engineering of designed nanoparticles (chemistry, size and surface charge) for in vivo lung 
drug delivery is required to optimise the performance. To date, CS structure modification has 
mostly been carried out at the amino groups at the C2 position (Figure 2) and the prepared 
particles have not been fully investigated for toxicity, drug accumulation and release. In 
future, more derivatives of CS with modifications at C6 or both the C2 and C6 sites will be 
prepared and their manufacturing technologies, physicochemical properties, extent of 
sustained drug release, and importantly, the toxicities in human organs will be studied.   Most 
of the major cross-linkers, surfactants and certain grafting agents used in the preparation of 
CS nanoparticles are not free from toxicity, which is essential to account for long term 
exposure. The biodegradability, biodistribution and biocompatibility of CS and especially its 
derivatives are not fully understood and therefore, in future, careful investigations are 
required. Due to the characteristics of its chemical structure, cross-linkers are often required; 
however, the optimum cross-linker(s) for the formation of NPs to needs be identified. 
Currently, TPP is widely used as a less toxic cross-linker, but more studies are required to 
search for better cross-linkers with reduced or no toxicity. Few in vivo studies have been 
carried out so far and therefore, a deeper knowledge on the in vitro/in vivo toxicity of both 
CS and its derivatives for prolonged release drug delivery needs to be investigated in detail. 
To strengthen the polymer based nanoparticulate lung delivery of various drugs, 
multidisciplinary researchers, i.e., polymer scientists, biologists, immunologists, pharmacists, 
and medical practitioners need to work together. Translation of information from lung 
delivery to animals (most frequently used mouse and rat models) to humans is very difficult 
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because of the significant differences between the physiology of the respiratory tract of 
animals and humans. In addition, the administration routes used for animal models are not 
suitable for human use. It is extremely difﬁcult to evaluate and justify the lung delivery 
efﬁciency of the prepared formulations before considering them for clinical studies. 
Therefore, the selection of appropriate lung drug delivery models, which will result in 
achieving their translation into clinical trials is essential. Future research will focus on the 
appropriateness of the inhaled drug delivery technology such as design of polymer conjugate 
with reduced toxicity, optimization of NP fabrication and cross-linking, improved solubility 
of hydrophobic drugs, and the capability of accommodating both hydrophilic and 
hydrophobic drugs. CS based nanoparticulate drug delivery will create a promising roadmap 
to deliver a large number of therapeutic agents into deep lungs for both local and systemic 
effects. 
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Table 1: Drug encapsulated CS micro/nanoparticles investigated for lung delivery 
Drugs Carrier Formulation/ 
delivery 
Main findings Ref. 
Proteins/ 
peptide 
    
Insulin CS+ mannitol Spray dried drug 
loaded   
microparticles; in 
vitro drug release 
Reduced FPF compared 
to other formulations 
61
 
Insulin CS Microencapsulated 
insulin loaded CS 
NP; rat model  
Improved absorption for 
systemic action 
48, 80
 
Insulin CS; TMCS  Supercriticaly (SCF) 
produced insulin 
coated CS 
microparticles 
SCF drying was a 
promising technique to 
prepare inhalable insulin 
loaded CS microparticles 
62
 
Palmitic acid 
modified 
Extendin 4 (Pal-
Ex4) 
GCS + 
PLGA 
Nebulization of NPs 
in rats 
Improved cellular 
uptake; delayed release; 
hypoglycemic efficacy 
was 3.1-fold higher than 
that of unmodified drug 
31
 
Elcatonin CS + 
liposome 
Drug loaded 
liposome NPs coated 
with CS 
Enhanced absorption and 
therapeutic action;  
prolonged drug release 
32
 
Calcitonin 
(hormone) 
CS +PLGA CS-modified PLGA 
nanospheres loaded 
with drug  
enhanced the absorption 
by opening the 
intercellular tight 
junctions; sustained 
release profile 
8, 24
 
Heparin (LMW) CS and GCS Intratracheal 
administration of NP 
in mice 
Increased blood 
coagulation time with 
respect to pure heparin  
51
 
Octreotide CS and TMC Intra-tracheal 
instillation in rats 
Permeation enhancer; 
sustained release; low 
toxicity 
25
 
Antibacterial/ 
antitubercular 
    
Isoniazid CS + 
lactose+ 
mannitol + 
maltodextrin  
Drug-loaded CS NPs 
spray dried with 
lactose, mannitol and 
maltodextrin alone 
or with leucine. 
CS based drug decreased 
activity against M.avium; 
leucine increased 
dispersibility (FPF 45%) 
73
 
Levofloxacin CS  In vitro lung Improved dispersion, 
53
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deposition from DPI, 
release and 
antimicrobial 
activities 
antimicrobial activities 
with controlled release 
profile 
Ciprofloxacin CS, CS + DX  Spray dried drug 
loaded CS or 
CS+DX inhalable 
microparticles   
Promising  activity 
against P.aeruginosa and 
S. aureus; controlled 
drug release; safe on lung 
epithelial cells  
69
 
Rifampicin + 
isoniazid 
CS Spray dried drug 
loaded CS NPs for 
nebulization in rat  
Encapsulated drug was 
more effective against 
the mycobacterium than 
free drug; controlled 
release 
76
 
Rifampicin + 
isoniazid 
CS + guar 
gum 
CS coated and guar 
gum coated CS 
particles, spray dried 
with mannitol and 
leucine    
improved therapeutic 
activity against 
tuberculosis with reduced 
cytotoxicity  
29
 
Rifampicin CS +XG + 
liposome 
(chitosome) 
Freeze dried drug 
loaded liposome 
coated with CS and 
XG microparticles  
improved in vitro drug 
deposition  
75
 
Tobramycin CS + PLGA Intratracheal 
administration in rats 
for tuberculosis 
Modified surface  
influenced better 
aerosolization and 
deposition  
7
 
Ethambutol CS  In vitro lung delivery 
for tuberculosis 
lower toxicity, higher 
potency and better 
permeation than the pure 
drug 
72
 
Dapsone CS Dapsone-loaded CS 
microcapsules for in 
vitro lung delivery 
High FPF (50%) and low 
toxicity; effective against 
Pneumocystis carinii 
pneumonia  
77
 
Ofloxacin CS Drug loaded CS 
microsphere 
Improved drug uptake; 
reduced the duration to 
cure tuberculosis 
52
 
Moxifloxacin CS Spray dried drug 
loaded CS  
microsphere 
Sustained drug release up 
to 4 days 
70
 
Rifampicin + 
Rifabutin 
CS + lactose Spray dried drug 
loaded CS particles 
blended with lactose 
carriers  
Improved, targeted and 
efficient delivery system 
for the treatment of 
tuberculosis 
60
 
Gentamicin CS + 
fucoidan (F) 
Drug loaded NPs   
against K. 
pneumoniae; intra-
tracheal rat model 
Superior antimicrobial 
capabilities with reduced 
toxicity;  sustained 
release profile 
78 
Clarithromycin CS + leucine Spray dried particles Improved dispersibility; 
71 
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for in vitro delivery no toxicity on Calu-3 
cells observed 
Clindamycin CS + lactose Spray dried powders 
for vitro drug 
dispersion 
Improved dispersion with 
sustained release 
57
   
Vancomycin CS 
+liposomes 
(chitosomes) 
Drug loaded 
liposomes modified 
with CS; nebulized 
by rat 
Improved drug transport, 
tissue uptake and 
systemic circulation 
110
 
Anticancer     
Paclitaxel CS + PLGA CS modified 
paclitaxel loaded 
PLGA NPs delivery 
into mice lung 
Increased uptake and 
cytotoxicity against lung 
cancer cell line (A549)  
81
 
Docetaxel CS Drug-loaded CS 
microspheres; in 
vitro and in vivo 
studies 
Sustained release of 
DTX;   increased the 
accumulation of drug in 
target sites 
54
 
Cisplatin CS   NPs of anionic 
cisplatin -alginate 
complex with 
cationic CS 
Particles with lowest 
positive zeta potential 
were more active than 
the pure drug on A549 
human cells 
82
 
Cisplatin CS  Drug loaded CS 
microspheres; 
emulsification 
method; in vitro test  
Higher IC50 against A549 
and HOP 62 lung cancer 
cell lines; slow release 
12
 
Methoxy-
estradiol  
PLGA + CS Spray dried NPS; 
Lung delivery in  rat 
model 
Improved dispersibility 
with sustained release; 
enhanced cytotoxicity 
without inflammation; 
effective and safe for  
lung cancer 
59
 
Anti-asthma     
Salbutamol 
sulfate 
CS + lactose Spray dried CS 
microspheres of drug 
and lactose based 
dry powder  
Delayed drug release 
83
 
Theophylline CM-CS + β-
cyclodextrin  
Spray dried 
microspheres for 
lung delivery 
Biocompatible;  potential 
carrier for lung drug 
delivery 
18
 
Terbutaline 
sulfate + 
Beclomethasone 
dipropionate 
CS + leucine In vitro dispersibility 
and release studies 
of spray dried drug   
Improved  dispersibility 
with sustained release 
profile 
30
 
Beclomethasone 
dipropionate 
CS + lactose 
+ leucine 
In vitro dispersibility 
and release studies 
of spray dried 
powder 
Delayed drug release 
56
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Budesonide  Spray dried 
drug coated 
large porous 
CS particles  
In-vitro and rat 
model 
Improved half life and 
bioavailability 
85
 
Others     
Itraconazole 
(antifungal) 
CS + lactose 
+ mannitol + 
leucine 
In vitro drug 
dispersion 
Improved the 
aerosolization; sustained 
release 
87
 
Carvedilol (anti-
hypertensive) 
CS + PEVA+ 
mannitol/ 
lactose 
Drug loaded PEVA 
NPs coated with CS 
and spray dried with 
lactose/ mannitol  
Mucoadhesive and 
controlled release; higher 
FPF (58.8%)  
88
 
 
Note: DX: Dextran; XG: Xanthan gum; GCS: glycol CS (3); CM CS: carboxymethyl CS (4); 
PEVA: poly(ethylene-co-vinyl acetate); TMCS: N-trimethyl chitosan (2). 
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Table 2: CS based lung delivery of genes  
Drug 
molecule 
Formulation In vivo model Main findings Ref. 
pDNA Spray dried 
CS coated 
pDNA NPs 
In vitro lung 
delivery 
CS improved 
dispersibility; enhanced 
level of reporter gene 
expression  
90
 
DNA CS + PLGA Nebulization 
of NPs in rats 
Higher 
cytocompatibility with 
lung cells; sustained 
release 
46
 
pDNA CS Microparticles 
delivered in 
mouse 
Increased the luciferase 
activity and stability of 
pDNA powder 
91, 92
 
Antisense 
2'-O-Me 
RNA 
(OMR) 
CS coated 
PLGA NPs 
Nanoplexes 
with antisense 
2'-O-Me RNA 
(OMR); rat 
model 
Produced higher 
cellular OMR uptake; 
good local tolerability 
96
 
-
interferon 
CS + mannitol CS-INF 
complex; intra-
tracheal mouse 
model 
Promising gene therapy 
to treat lung cancer or 
metastasis 
93
 
luciferase 
reporter 
plasmid 
(CS-
pLuc) 
CS intratracheally 
administered 
into  Balb/c  
mice 
Activated genes 
involved in reaction to 
stress, such as DNA 
damage repair 
97
 
siRNA CS siRNA 
encapsulated 
crosslinked CS 
NPs for 
nebulization 
High cell viability at the 
highest CS conc.;  
potential for siRNA 
delivery to the lungs  
94
 
siRNA CS+ 
oligopeptide 
Intratracheal 
administration 
of NPs in 
mouce model 
Modified CS NPs were 
more effective in 
delivering genes 
compared with pure CS 
95
 
 
pDNA: plasmid DNA 
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Table 3: Nanoparticles of CS encapsulated lung vaccine delivery 
Drug molecule Formul
ation 
In vivo model Main findings Ref. 
Diphtheria toxoid CS  DPI  formulation 
delivery in guinea 
pig 
induced strong 
immune response 
(induction of IgA 
antibody)  
104
 
The pHSP65-pep 
DNA complexed 
with CS 
CS Intranasal, mice 
model 
induced specific 
mucosal Th1 response 
and SIgA level; better 
than pure vaccine 
102
 
DNA vaccine 
(pVAX(HBc)DNA) 
CS Intratracheal 
administration in 
mouse model 
CS NPs were safe for 
effective DNA 
delivery 
101
 
DNA vaccine 
(HLA-A*0201-
restricted T-cell) 
CS DNA vaccine 
complexed with 
CS; mouse model 
Increased 
immunogenicity 
against tuberculosis  
27
 
pDNA  CS CS coated DNA 
NPs with   
pam3Cys; ex vivo 
cell model 
Elevated IL-8 and 
TNF-α level 
103
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Table 4: Drug encapsulated particles of CS derivatives investigated for lung delivery 
Formulation Drug molecule In vivo model Main findings Ref. 
CS or 8 Levofloxacin Spray dried drug + CS 
or 8 
hydrophobic 8 enhanced 
dispersibility of NP and 
noncytoxic  
68
 
14 siRNA NPs nebulised in mice Decreased cytotoxicity; 
enhanced the transfection 
efficiency 
106
 
12 Calcitonin Intratracheal 
administration to rat  
Enhanced mucoadhesion; 
pronounced 
hypocalcemic effect 
34
 
18, 19 Sodium 
fluorescein 
(model drug) 
Microparticles for in 
vitro delivery 
Sustained drug release 
107
 
19 
 
BSA BSA loaded alginate 
IPN hydrogel 
microspheres; in vitro 
delivery  
Sustained drug release 
111
 
19 Ciprofloxacin Dry powder of NPs 
delivered into rat lungs 
Higher drug 
concentration in the 
lungs; sustained released 
profile 
108
 
13 PTEN Aerosols of UAC-
PTEN were delivered 
into K-rasLA1 lung 
cancer mice model 
Suppressed lung tumor, 
Akt-related signals, and 
cell cycle regulation 
105
 
15-17 siRNA siRNA coated CS 
complex NPs delivered 
into mice lung 
Enhanced cellular uptake 
and the gene silencing 
efficiency CS/siRNA 
NPs 
95
 
5 Diltiazem 
hydrochloride 
(DH) 
DH encapsulated  CS 
and conjugated CS NPs 
Low toxicity, enhanced 
dispersibility, rapid and 
prolonged drug release  
11, 43
 
 
PHCS: Phthalolyl CS; NPHCS: N-Phthalolyl CS; PTEN: Phosphatase and tension homolog 
deleted on chromosome 10. 
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Figures 
 
 
 
 
 
 
Fig. 1 The structure of the repeating units of chitosan (CS) 1 and some derivatives, N-
trimethyl chitosan (2), glycol chitosan (3) and carboxymethyl chitosan (4). Note that CS 
preparations contain varying amounts of N-acetyl groups but for simplicity CS derivatives 
will be depicted herein without them. 
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Fig. 2 Chemical structures of synthetic chitosan polymers investigated for lung drug delivery. 
For simplicity, the structures do not depict the presence of unmodified amino groups or N-
acetyl groups which is some cases make up the majority of the monosaccharide units in the 
polymer, depending on the degree of substitution. 
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Fig. 3 Chitosan based lung delivery of various therapeutic agents investigated 
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Fig. 4 Schematic illustration of the preparation of gentamicin loaded-CS/F NPs prepared by 
an ionotropic cross-linking method (Reproduced with permission).
78
 
 
 
Chitosan 
(CS) 
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Fig.5 Illustration for the preparation of dry, swellable, nano-in-micro hydrogel particles using 
PEG grafted CS (Reproduced with permission).
108
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Fig.6. A. Leucine-conjugated CS nanoparticles showing hydrophilic and hydrophobic 
domains and the hypothesised nanoparticle surface with a conformation that changes to be 
hydrophobic in air (for dispersion from DPI formulation) and hydrophilic in water (for drug 
release); B. In vitro rapid and prolonged release profiles of drug from conjugated chitosan 
NPs; C. Enhanced drug deposition (fine particle dose FPD) from conjugated CS NPs 
(Reproduced with permission).
11
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